A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma.

ABSTRACT:

Lessons learned

Treatment with the Aurora kinase A inhibitor yields often durable disease control, but limited tumor regression, in heavily pretreated patients with unresectable malignant pleural or peritoneal mesothelioma. In a limited sample size, MYC copy-number gain or gene amplification, a candidate predictive biomarker for alisertib, did not correlate with improved response numbers or patient outcomes.

Background

Malignant mesothelioma is an aggressive disease for which few effective therapies are available. The Aurora family kinases are critical for mitotic fidelity and highly expressed in mesothelioma, wherein their inhibition leads to growth arrest in vitro. We evaluated the efficacy of alisertib, an Aurora A kinase inhibitor, in relapsed malignant mesothelioma.

SUBMITTER: Gay CM 

PROVIDER: S-EPMC7543335 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature